BioSpace News Archive

Pharmapack Europe: Innovation, Networking and Education

Pharmapack 2021 will showcase many of the latest innovations in the industry and bring the entire community together to help foster new advances.

August 24, 2021
·
5 min read
BioMidwest

Cleveland-Cliffs Reports Final Results of the Company-Wide COVID Vaccination Incentive Program

Cleveland-Cliffs Inc. (NYSE: CLF) today announced the results of its COVID-19 Vaccination Incentive Program.

August 24, 2021
·
2 min read
Business

MedX Health Corp. Announces Second Quarter 2021 Results

MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its results for the three and six-months ended June 30, 2021, which are also available on SEDAR (www.sedar.com).

August 24, 2021
·
4 min read
HEXO Corp. Closes US$144.8 Million Underwritten Public Offering

HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced the closing of its previously announced underwritten public offering (the “Offering”) for total gross proceeds to the Company of US$144,786,070.80.

August 24, 2021
·
4 min read
Drug Development

Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication

Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 in China for chronic hepatitis B (CHB) indication.

August 24, 2021
·
4 min read
Drug Development

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) , today announced that its SARS-CoV-2 (virus that causes COVID-19) neutralizing monoclonal antibody combination therapy, BRII-196/BRII-198 (“combination BRII-196/BRII-198"),

August 24, 2021
·
7 min read